Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | Unknown | — |
The patient received first, and second dose of Rabavert and having late for the third dose; Case reference number US-BN-2024-002776 is a spontaneous case initially received from a pharmacist via Med Communications (reference number: USBAV24-3013) on 13-Nov-2024 and concerns a male patient of unknown age. The patient's medical history and concomitant medication details were not provided. On unspecified date, the patient was vaccinated with the first and second dose of RabAvert along with device constituents prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown), at an unknown dose, route, or site of administration for post-exposure prophylaxis. On unspecified date, reported as last Sunday, the patient was supposed to get third dose of RabAvert, however patient came today and administered the third dose of RabAvert along with device constituents prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown), at an unknown dose, route, or site of administration, which was late for the administration (explicitly coded as Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Rabavert. No further information was provided.; Reporter's Comments: A male patient of unknown age was late for the administration of the third dose of RabAvert, after the patient was vaccinated with the first and the second dose of RabAvert along with device constituents prefilled syringe, needle for injection, and needle for reconstitution for post-exposure prophylaxis, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age was late for the administration of the third dose of RabAvert, after the patient was vaccinated with the first and the second dose of RabAvert along with device constituents prefilled syringe, needle for injection, and needle for reconstitution for post-exposure prophylaxis, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None